John Hannigan Joins OpSens as Chief Financial Officer

OpSens Inc. has named John Hannigan as its new chief financial officer. 

“We are very pleased John Hannigan has agreed to become our new chief financial officer,” OpSens President/CEO Louis Laflamme said. “John’s proven experience will be beneficial in implementing OpSens’ financial and growth strategies.” 

Hannigan has more than 22 years of proven financial expertise with domestic and international companies. Prior to joining the company, he was vice president of Finance at diaMentis Inc., a Quebec City based company developing a simple and reliable solution in personalized medicine, intended to be used by clinicians as a support for making faster, more objective, and accurate diagnoses of mental health disorders.

Before diaMentis, Hannigan worked in various senior financial management positions from August 2015 to December 2020 for IPL Plastics Inc., a sustainable packaging solutions company listed on the Toronto Stock Exchange. IPL Plastics annual revenue was $600 million when it was acquired in 2020.

Hannigan began his career with KPMG in Ireland, working with the firm from November 2000 to August 2015. His client list was extensive and included listed and private companies with an international presence.

“I am very enthusiastic to join the OpSens team during this exciting period for the company as it ramps up its commercial activities for its products including the newest, the SavvyWire,” Hannigan said. 
  
OpSens focuses mainly on cardiology. The company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used to diagnose and treat more than 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, United Kingdom, Japan, and Canada.. 

OpSens has received U.S. Food and Drug Administration clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a three-in-one solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access. OpSens’ SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to leave the hospital earlier, sometimes the same day. 

The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027.

OpSens is also involved in industrial activities in developing, manufacturing, and installing fiber optic sensing solutions for critical applications.